uploads///Analysts Reco

Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

By

Dec. 4 2020, Updated 10:53 a.m. ET

Recent collaborations

In July 2017, Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS) entered into a clinical collaboration agreement to evaluate Bristol-Myers Squibb’s Opdivo and Clovis Oncology’s Rubraca combination therapy for the treatment of advanced ovarian cancer and advanced triple-negative breast cancers (or TNBC).

Bristol-Myers Squibb and Clovis Oncology plan to conduct the Phase 3 trial. This trial would evaluate the safety and efficacy of Rubraca and Opdivo combination therapy as a first-line maintenance treatment in newly diagnosed patients with stage 3/4 high-grade ovarian, fallopian tube, or primary peritoneal cancer. These patients must have undergone a platinum-based chemotherapy, compared to Rubraca therapy, Opdivo therapy, and placebo therapy.

Article continues below advertisement

Bristol-Myers Squibb and Clovis Oncology also plan to conduct a Phase 3 pivotal trial. This trial would evaluate the safety and efficacy of Rubraca and Opdivo combination therapy as a first-line maintenance treatment in individuals with recurrent, locally advanced inoperable TNBC related with a homologous recombination deficiency (or HRD). This treatment would be compared with Rubraca therapy, Opdivo therapy, and chemotherapy.

The collaboration between Bristol-Myers Squibb and Clovis Oncology also includes a Phase 3 trial to evaluate the safety and efficacy of Rubraca and Opdivo combination therapy. This therapy would involve the treatment of individuals with metastatic castration-resistant prostate cancer (or mCRPC).

Analysts’ recommendations

Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

Around 43% of these analysts suggested some form of a “buy” rating. On August 15, 2017, Bristol-Myers Squibb had a consensus 12-month target price of $57.32. The Vanguard Health Care ETF (VHT) invests ~2.8% of its total portfolio in Bristol-Myers Squibb.

Peers’ ratings

Of the 22 analysts covering Pfizer (PFE) in August 2017, one analyst recommended a “strong buy,” while ten analysts suggested a “buy.” Ten analysts tracking Pfizer suggested a “hold,” while one analyst recommended a “strong sell.”

Around 50% of the analysts tracking Pfizer in August recommended some form of a “buy” rating. On August 15, Pfizer had a consensus 12-month target price of $37.45, which represents an ~12.4% return on investment.

Of the 22 analysts tracking Johnson & Johnson (JNJ) in August 2017, two analysts suggested a “strong buy,” and eight analysts suggested a “buy.” Ten analysts tracking Johnson & Johnson recommended a “hold,” one analyst recommended a “sell,” and one analyst recommended a “strong sell.”

Around 50% of the analysts tracking JNJ in August 2017 recommended some form of a “buy” rating. In August, Johnson & Johnson had a consensus 12-month target price of $137.05, which represents an ~2.7% return on investment.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.